Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daewoong Pharmaceutical To In-license Almirall's COPD drug Eklira In Korea

This article was originally published in PharmAsia News

Executive Summary

Daewoong signs in-licensing deal just one week before Eklira – a product with a history of clinical setbacks – faces U.S. FDA advisory committee meeting.


Related Content

Korean Analysts Retain Optimism For Daewoong Pharmaceutical On Early Pipeline and In-licensing
Positive COPD Data Allows Forest To File For Approval of Eklira in 2011


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts